97
Views
29
CrossRef citations to date
0
Altmetric
Original

Testosterone addition during menopausal hormone therapy: effects on mammographic breast density

, , , , &
Pages 155-163 | Received 31 Jul 2006, Accepted 08 Dec 2006, Published online: 03 Jul 2009

References

  • Shifren J L, Braunstein G D, Simo J A, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000; 343: 682–688
  • Sherwin B B. Use of combined estrogen–androgen preparations in the postmenopause: evidence from clinical studies. Int J Fertil Womens Med 1998; 43: 98–103
  • Davis S R, McCloud P I, Strauss B J, et al. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995; 21: 227–236
  • Rosenberg M J, King T D, Timmons M C. Estrogen–androgen for hormone replacement. A rewiew. J Reprod Med 1997; 42: 394–404
  • Gelfand M. It might be wise to consider adding androgen to the estrogen or estrogen–progestin regimens in the appropriate women. Menopause 2004; 11: 505–507
  • Chlebowski R T, Hendrix S L, Langer R D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003; 289: 3243–3253
  • Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419–427
  • Cauley J A, Lucas F L, Kuller L H, et al. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer: study of Osteoporotic Fractures Research Group. Ann Intern Med 1999; 130: 270–277
  • Key T, Appleby P, Barnes I, et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002; 94: 606–616
  • Somboonporn W, Davis S. Testosterone effects on the breast: implications for testosterone therapy for women. Endocr Rev 2004; 25: 374–388
  • Dimitrakakis C, Jones R, Liu A, et al. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. Menopause 2004; 11: 531–535
  • Tamimi R M, Hankinson S E, Chen W Y, et al. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Intern Med 2006; 166: 1483–1489
  • Boyd N F, Rommens J M, Vogt K, et al. Mammographic density as an intermediate phenotype for breast cancer. Lancet Oncol 2005; 6: 798–808
  • Warren R. Hormones and mammographic breast density. Maturitas 2004; 49: 67–78
  • Harvey J A, Bovbjerg V E. Quantitative assessment of mammographic breast density: relationship with breast cancer risk. Radiology 2004; 230: 29–41
  • Lundström E, Wilczek B, von Palffy Z, et al. Mammographic breast density during hormone replacement therapy: differences according to treatment. Am J Obstet Gynecol 1999; 181: 348–352
  • Conner P, Svane G, Azavedo E, et al. Mammographic breast density, hormones, and growth factors during continuous combined hormone therapy. Fertil Steril 2004; 81: 1617–1623
  • Hofling M, Linden Hirschberg A, Skoog L, et al. Testosterone addition inhibits estrogen–progestogen induced breast cell proliferation in postmenopausal women. Menopause Nov 13, 2006, E-pub
  • Lundström E, Wilczek B, von Palffy Z, et al. Mammographic breast density during hormone replacement therapy: effects of continuous combination, unopposed transdermal and low potency estrogen regimens. Climacteric 2001; 4: 42–48
  • Wolfe J N. Breast patterns as an index of risk for developing breast cancer. Am J Roentgenol 1976; 26: 1130–1139
  • Lundström E, Christow A, Kersemaekers W, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002; 186: 717–722
  • Byng J W, Boyd N F, Fishell E, et al. The quantitative analysis of mammographic densities. Phys Med Biol 1994; 39: 1629–1638
  • Byng J W, Boyd N F, Fishell E, et al. Automated analysis of mammographic densities. Phys Med Biol 1996; 41: 909–923
  • Södergård R, Bäckström T, Shanbag V, et al. Calculation of free and bound fractions of testosterone and estradiol-17β to plasma proteins at body temperature. J Steroid Biochem 1982; 187: 801–804
  • Yaffe M, Hendrix S, Pike M, et al. Is mammographic density, as currently measured, a robust surrogate marker for breast cancer?. Gynecol Endocrinol 2005; 21: 17–21
  • Greendale G A, Reboussin B A, Sie A, et al. Effects of estrogen and estrogen–progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestogen Interventions (PEPI) Investigators. Ann Intern Med 1999; 130: 262–269
  • Guo Y P, Martin L, Hanna W, et al. Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomarkers Prev 2001; 10: 243–248
  • Alowami S, Troup S, Al-Haddad S, et al. Mammographic density is related to stroma and stromal proteogycan expression. Breast Cancer Res 2003; 5: 129–135
  • Conner P. Hormone therapy and the breast – aspects on proliferation, apoptosis and mammographic density. Karolinska Institutet, Stockholm 2004, Doctoral Thesis
  • Lundström E, Söderqvist G, Svane G, et al. Digitized assessment of mammographic breast density during low dose intrauterine levonorgestrel in continuous combination with oral estradiol valerate. A pilot study. Fertil Steril 2006; 85: 989–995
  • Conner P, Söderqvist G, Skoog L, et al. Breast cell proliferation in postmenopausal women during HRT evaluated through fine needle aspiration cytology. Breast Cancer Res 2003; 78: 159–165
  • Lundström E, Sahlin L, Skoog L, et al. Expression of Syndecan-1 in postmenopausal breast tissue according to mammographic density. Climacteric 2006; 9: 277–282
  • Hofling M, Carlström K, Azavedo E, et al. Different effects of tibolone and continous combined hormone replacement therapy on SHBG and free testosterone levels – an association with mammographic density. Gynecol Endocrinol 2005; 20: 110–115
  • Warren R, Skinner J, Sala E, et al. Associations among mammographic density, circulating sex hormones, and polymorphisms in sex hormone metabolism genes in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2006; 15: 1502–1508
  • Sutton-Tyrrell K, Wildman R P, Matthews K, et al. Sex hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal women enrolled in the Study of Women Across the Nation (SWAN). Circulation 2005; 111: 1242–1249
  • Kahn S M, Hryb D J, Nakhla A M, et al. Sex hormone-binding globulin is synthetized in target cells. J Endocrinol 2002; 175: 113–120
  • Conde I, Alfaro J M, Fraile B, et al. DAX-1 expression in human breast cancer: comparison with estrogen receptors ER-alfa, ER-beta and androgen receptor status. Breast Cancer Res 2004; 6: 140–148
  • Burak W E, Jr, Quinn A L, Farrar W B, et al. Androgens influence estrogen-induced responses in human breast carcinoma cells through cytochrome P450 aromatase. Breast Cancer Res Treat 1997; 44: 57–64

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.